Cargando…

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus

Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Satoshi, Oba, Kageyuki, Higa, Moritake, Arasaki, Osamu, Shimabukuro, Michio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356893/
https://www.ncbi.nlm.nih.gov/pubmed/32492927
http://dx.doi.org/10.3390/jcm9061675
_version_ 1783558587343175680
author Yamaguchi, Satoshi
Oba, Kageyuki
Higa, Moritake
Arasaki, Osamu
Shimabukuro, Michio
author_facet Yamaguchi, Satoshi
Oba, Kageyuki
Higa, Moritake
Arasaki, Osamu
Shimabukuro, Michio
author_sort Yamaguchi, Satoshi
collection PubMed
description Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power.
format Online
Article
Text
id pubmed-7356893
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73568932020-07-22 Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus Yamaguchi, Satoshi Oba, Kageyuki Higa, Moritake Arasaki, Osamu Shimabukuro, Michio J Clin Med Article Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power. MDPI 2020-06-01 /pmc/articles/PMC7356893/ /pubmed/32492927 http://dx.doi.org/10.3390/jcm9061675 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamaguchi, Satoshi
Oba, Kageyuki
Higa, Moritake
Arasaki, Osamu
Shimabukuro, Michio
Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
title Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
title_full Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
title_fullStr Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
title_full_unstemmed Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
title_short Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
title_sort age-dependent efficacy of ezetimibe for low-density lipoprotein cholesterol reduction in japanese patients with or without type 2 diabetes mellitus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356893/
https://www.ncbi.nlm.nih.gov/pubmed/32492927
http://dx.doi.org/10.3390/jcm9061675
work_keys_str_mv AT yamaguchisatoshi agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus
AT obakageyuki agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus
AT higamoritake agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus
AT arasakiosamu agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus
AT shimabukuromichio agedependentefficacyofezetimibeforlowdensitylipoproteincholesterolreductioninjapanesepatientswithorwithouttype2diabetesmellitus